Sol-Gel Technologies Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments
November 11, 2021 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel attains a profitable quarter, reporting total revenues of $8.8 million, net income of $1.3 million and EPS of $0.06Recently obtained FDA approval of TWYNEO® triggers a $3.5 million milestone...
Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference
November 09, 2021 07:05 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic...
Sol-Gel Technologies Announces Sale of Generic Dermatology Portfolio to Partner Padagis for $21 Million
November 04, 2021 07:30 ET
|
Sol-Gel Technologies Ltd.
- Sol-Gel to receive $21 million over 24 months in exchange for the transfer of its rights to two marketed generic drugs and eight unapproved generic programs - Sol-Gel to retain two generic...
Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference
September 22, 2021 07:30 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic...
Sol-Gel Technologies to Present at Upcoming H.C. Wainwright Global Investment Conference
September 09, 2021 08:30 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic...
Sol-Gel Technologies Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments
August 04, 2021 07:05 ET
|
Sol-Gel Technologies Ltd.
Recently obtained FDA approval of TWYNEO® triggers milestone payment from GaldermaExclusive license agreements with Galderma for U.S. commercialization of EPSOLAY® and TWYNEOSol-Gel advancing its...
Sol-Gel Technologies Announces FDA Approval of TWYNEO®
July 27, 2021 09:15 ET
|
Sol-Gel Technologies Ltd.
TWYNEO®, a once-daily cream treatment for acne vulgaris, is the first FDA-approved fixed-dose combination of tretinoin and benzoyl peroxideTWYNEO utilizes Sol-Gel’s proprietary microencapsulation...
Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021
July 20, 2021 07:05 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded...
Sol-Gel Announces Pipeline Update and Future Development Plans
June 28, 2021 05:10 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel investigational SGT-510 was found to be more effective than roflumilast cream, 0.3%, in a human xenograft psoriasis animal modelSol-Gel is developing tapinarof cream, 1%, aiming to offer...
Sol-Gel Technologies to Present at Upcoming Jefferies Healthcare Conference and Raymond James Human Health Innovation Conference
May 27, 2021 07:00 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and...